← Leaderboards
John W. Newcomer
Washington University
$11,123,197
Attributed
$11,446,709
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$11,446,709 · 21
By mechanism
R01$10,062,117 · 3
R34$647,025 · 1
M01$548,737 · 16
K02$188,830 · 1
Top collaborators
- Ginger E Nicol3 shared
Most similar at Washington University
Same institution · by research overlap
- Samuel Klein$33,055,933
- Ginger E Nicol$3,499,533
- Kevin Aaron Roth$8,308,976
- Jeffrey Ivan Gordon$32,802,915
- Dan W Haupt$977,321
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectSchizophreniaAntipsychotic AgentsObesityAgingHuman Therapy EvaluationDosageMagnetic Resonance ImagingInsulinGlucoseRisperidoneLipolysisBehavioral /Social Science Research TagMemoryMental Disorder ChemotherapyHormone Regulation /Control MechanismWeight GainCardiovascular DiseasesResearch PersonnelOverweightGlucose TolerancePsychosocialAdipose Tissue
Grant awards (53)
Adaptation of an Evidence-based Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Early Serious Mental Illness: iOTA-eSMI$209,787
R34 · FY2021 · MH
Adaptation of an Evidence-based Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Early Serious Mental Illness: iOTA-eSMI$207,531
R34 · FY2020 · MH
Adaptation of an Evidence-based Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Early Serious Mental Illness: iOTA-eSMI$229,707
R34 · FY2019 · MH
Metabolic Effects of Antipsychotics in Children$793,487
R01 · FY2010 · MH · contact PI
Metabolic Effects of Antipsychotics in Children$263,598
R01 · FY2010 · MH · contact PI
Metabolic Effects of Antipsychotics in Children$1,208,362
R01 · FY2009 · MH · contact PI
Metabolic Effects of Antipsychotics in Children$1,201,490
R01 · FY2008 · MH · contact PI
Metabolic Effects of Antipsychotics in Children$1,213,084
R01 · FY2007 · MH · contact PI
GLUCOSE AND LIPID METABOLISM ON ANTIPSYCHOTIC MEDICATION$29,280
M01 · FY2007 · RR · contact PI
METABOLIC EFFECTS OF ANTIPSYCHOTICS IN CHILDREN$12,065
M01 · FY2007 · RR · contact PI
ARIPIPRAZOLE IVGTT$8,674
M01 · FY2007 · RR · contact PI
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING HUMANS$3,388
M01 · FY2007 · RR · contact PI
METABOLIC EFFECTS OF ANTIPSYCHOTICS IN CHILDREN$813
M01 · FY2007 · RR · contact PI
KIDS KETAMINE$542
M01 · FY2007 · RR · contact PI
Metabolic Effects of Antipsychotics in Children$1,070,601
R01 · FY2006 · MH · contact PI
GLUCOSE AND LIPID METABOLISM ON ANTIPSYCHOTIC MEDICATION$84,129
M01 · FY2006 · RR · contact PI
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING HUMANS$45,396
M01 · FY2006 · RR · contact PI
ARIPIPRAZOLE IVGTT$25,405
M01 · FY2006 · RR · contact PI
KIDS KETAMINE$5,414
M01 · FY2006 · RR · contact PI
A PILOT STUDY OF METABOLIC EFFECT OF ANTIPSYCHOTICS IN CHILDREN$3,748
M01 · FY2006 · RR · contact PI
METABOLIC EFFECTS OF ANTIPSYCHOTICS IN CHILDREN$833
M01 · FY2006 · RR · contact PI
Antipsychotic Medication$656,685
R01 · FY2005 · MH
GLUCOSE AND LIPID METABOLISM ON ANTIPSYCHOTIC MEDICATION$72,706
M01 · FY2005 · RR
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING HUMANS$62,848
M01 · FY2005 · RR
GLUCOSE REGULATION DURING RISPERIDONE AND OLANZAPINE TREATMENT$6,572
M01 · FY2005 · RR
KIDS KETAMINE$5,751
M01 · FY2005 · RR
A PILOT STUDY OF METABOLIC EFFECT OF ANTIPSYCHOTICS IN CHILDREN$410
M01 · FY2005 · RR
Antipsychotic Medication$674,885
R01 · FY2004 · MH
Glucose and Lipid Metabolism on Antipsychotic Medication.$116,250
M01 · FY2004 · RR
Glucocorticoid Regulation of Memory Performance in Aging Humans.$43,115
M01 · FY2004 · RR
Glucose Regulation During Risperidone and Olanzapine Treatment.$19,801
M01 · FY2004 · RR
Kids Ketamine$1,597
M01 · FY2004 · RR
Antipsychotic Medication$656,296
R01 · FY2003 · MH
GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS$262,885
R01 · FY2003 · MH
Antipsychotic Medication$638,378
R01 · FY2002 · MH
GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS$262,885
R01 · FY2002 · MH
GLUCOSE ENHANCEMENT OF MEMORY/ATTENTION IN SCHIZOPHRENIA$0
M01 · FY2002 · RR
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING$0
M01 · FY2002 · RR
NEUROENDOCRINOLOGY OF MEMORY AND AGING IN SCHIZOPHRENIA$0
M01 · FY2002 · RR
PREVENTING NRH INDUCED SYMPTOMS IN HUMANS$0
M01 · FY2002 · RR
Antipsychotic Medication$542,688
R01 · FY2001 · MH
GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS$307,543
R01 · FY2001 · MH
NEUROCHEMICAL CONTROL OF MEMORY IN AGING SCHIZOPHRENICS$94,415
K02 · FY2001 · MH
PREVENTING NRH INDUCED SYMPTOMS IN HUMANS$0
M01 · FY2001 · RR
GLUCOSE ENHANCEMENT OF MEMORY/ATTENTION IN SCHIZOPHRENIA$0
M01 · FY2001 · RR
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING$0
M01 · FY2001 · RR
NEUROENDOCRINOLOGY OF MEMORY AND AGING IN SCHIZOPHRENIA$0
M01 · FY2001 · RR
GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS$309,250
R01 · FY2000 · MH
NEUROCHEMICAL CONTROL OF MEMORY IN AGING SCHIZOPHRENICS$94,415
K02 · FY2000 · MH
NEUROENDOCRINOLOGY OF MEMORY AND AGING IN SCHIZOPHRENIA$0
M01 · FY2000 · RR
GLUCOCORTICOID REGULATION OF MEMORY PERFORMANCE IN AGING$0
M01 · FY2000 · RR
GLUCOSE ENHANCEMENT OF MEMORY/ATTENTION IN SCHIZOPHRENIA$0
M01 · FY2000 · RR
PREVENTING NRH INDUCED SYMPTOMS IN HUMANS$0
M01 · FY2000 · RR